Clinical trial
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and…
NCT00361231 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00361231 |
|---|---|
| Title | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer |
| Official title | Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Genentech, Inc. Industry Sanofi Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Biliary Tract Cancer, Gallbladder Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Bevacizumab, Gemcitabine, Oxaliplatin |
| Enrollment | 35 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Aug 1, 2012 |
| First posted | Aug 8, 2006 |
| Last update posted | Feb 7, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: